Long-term LHRH-agonist treatment in metastatic breast cancer as a single treatment and in combination with other additive endocrine treatments

Schally A V, Arimura A, Coy D H: Recent approaches to fertility control based on derivates of LH-RH, in Munson P L, Diczfalusy E, Glover J, Olson R E (eds):Vitamins and Hormones, p. 257. New York, Academic Press (1980).

Sandow J: Gonadotropic and antigonadotropic actions of LH-RH analogues, in Müller E E, Macleod R M (eds):Neuroendocrine Perspectives, vol. 1, p. 339. Amsterdam, Elsevier Biomedical Press (1982).

Corbin A: From contraception to cancer: a review of the therapeutic applications of LHRH analogues as antitumor agents.Yale J Biol Med 55, 27 (1982).

Furr B J A, Nicholson R I: Use of analogues of luteinizing hormone-releasing hormone for the treatment of cancer.J Reprod Fert 64, 529 (1982).

Sandow J, Von Rechenberg W, Terzabek G, Stoll W: Pituitary gonadotropin inhibition by a highly active analog of luteinizing hormone-releasing hormone.Fertil Steril 30, 205 (1978).

Danguy A, Legros N, Heuson-Stiennon J A, Pasteels J L, Atassi G, Heuson J C: Effects of a gonadotropinreleasing hormone (GnRH) analogue (A-43818) on 7,12-dimethylbenz(a)anthracene-induced rat mammary tumours. Histological and endocrine studies.Eur J Cancer 13, 1089 (1977).

Lamberts S W J, Uitterlinden P, Zuiderwijk-Roest J M, Bons-van Evelingen E G, de Jong F H: Effects of a luteinizing hormone-releasing hormone analog and tamoxifen in the growth of an estrogen-induced prolactin-secreting rat pituitary tumor and its influence on pituitary gonadotropins.Endocrinology 108, 1878 (1981).

Sandow J, Von Rechenberg W, Jerzabek G, Engelbart K, Kuhl H, Fraser H: Hypothalamic-pituitary-testicular function in rats after supraphysiological doses of a highly active LRH analogue (buserelin).Acta Endocrinol 94, 489 (1980).

Pedroza E, Vilchez-Martinez J A, Coy D H, Arimura A, Schally A V: Reduction of LH-RH pituitary and estradiol uterine binding sites by a superactive analogue of luteinizing hormone-releasing hormone.Biochem Biophys Res Comm 95, 1056 (1980).

Sundaram K, Cav Y Q, Wang N S, Bardin C W, Rivier J, Vale W: Inhibition of the action of sex steroids by gonadotropin releasing hormone (GnRH) agonists: a new biological effect.Life Sci 28, 83 (1981).

Lecomte P, Wang N S, Sundaram K, Rivier J, Vale W, Bardin C W: The anti-androgenic action of gonadotropin-releasing hormone and its agonists on the mouse kidney.Endocrinology 110 1 (1982).

DeSombre E R, Johnson E S, White W F: Regression of rat mammary tumors affected by a gonadoliberin analog.Cancer Res 36, 3830 (1976).

Nicholson R I, Maynard P V: Anti-tumour activity of I.C.I.-118630, a new potent luteinizing hormone-releasing hormone agonist.Br J Cancer 39, 268 (1979).

Redding T W, Schally A V: Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp6 analogues of luteinizing hormone-releasing hormone.Proc nat Acad Sci 78, 6509 (1981).

Klijn J G M, de Jong F H: Treatment with a luteinizing hormone-releasing hormone analogue (Buserelin) in premenopausal patients with metastatic breast cancer.Lancet 1, 1213 (1982).

Klijn J G M, de Jong F H, Blonk-van der Wijst J, Alexieva-Figusch J, Lamberts S W J: Effects of a LHRH-agonist (alone and with tamoxifen) in premenopausal women with metastatic breast cancer.European Society for Medical Oncology, Nice, Cancer Chemotherapy and Pharmacology, Suppl.9, 28 (1982).

Klijn J G M, Lamberts S W J, de Jong F H, Docter R, van Dongen K J, Birkerhäger J C: The importance of pituitary tumour size in, patients with hyperprolactinaemia in relation to hormonal variables and extrasellar extension of tumour.Clin Endocrinol 12, 341 (1980).

Matsuzawa A, Yamamoto T: Enhanced and reversed growthin vivo of a pregnancy-dependent mouse mammary tumor (TPDMT-n) by a gonadotropin-releasing hormone agonist analog.Eur J Cancer clin Oncol 18, 495 (1982).

Tolis G, Ackman D, Stellos A,et al.: Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists.Proc nat Acad Sci 79, 1658 (1982).

Borgmann V, Hardt W, Schmidt-Gollwitzer M, Adenauer H, Nagel R: Sustained suppression of testosterone production by the luteinizing hormone-releasing hormone agonist Buserelin in patients with advanced prostate carcinoma.Lancet 1, 1097 (1982).

Klijn J G M, de Jong F H, Lamberts S W J: LHRH-agonist treatment of prostate cancer.Acta Endocrinologica Congress, Stockholm, June 1983.